Kişisel Profil:

Araştırma metodolojisi ve veri analizi konularında deneyimli bir tıbbi onkolog. Dinamik, yaratıcı, etkin iletişim becerilerine sahip.

Mezuniyet sonrası deneyim ve eğitim, ve görevler:

1. Medical Park Hastanesi, Tıbbi Onkoloji Bölümü, Antalya-TÜRKİYE (Nisan 2014- …)

Derece: Tıbbi Onkoloji Direktörü

- Bölüm başkanlığı

2.Akdeniz Üniversitesi, Tıp Fakültesi, Antalya-TÜRKİYE (Eylül 2009 – Mart 2014)

Derece: Tıbbi Onkoloji Profesörü (Eylül 2009’da olundu)

- Bölüm başkanlığı

3.Gold Coast Hospital, Dept. of Hematology and Oncology, Queensland-AVUSTRALYA (Kasım 2007 – Eylül 2008)

Derece: Tam zamanlı Tıbbi Onkolog

-Medikal onkoloji bölüm başkanı olarak çalışıldı, yatan ve ayaktan hasta tedavileri

-Hafta sonu ve hafta içi nöbetler

- Griffith University tıp öğrencileri eğitim programına katkı

4.Akdeniz Üniversitesi, Tıp Fakültesi , Antalya-TÜRKİYE (Nisan 2002 – Eylül 2009 )

Derece: Tıbbi Onkoloji Doçenti (Nisan 2002’de olundu)

- Eğitim ve araştırma ile yoğun meşguliyet

- Yatan ve ayaktan hasta tedavisi

- Onkoloji uzman eğitimiinde sorumluluk

5.Akdeniz Üniversitesi, Tıp Fakültesi, Antalya-TÜRKİYE (Mayıs 2000 – Nisan 2002)

Derece: Tıbbi Onkoloji Yardımcı Doçenti (Mayıs 2000’de olundu)

- Eğitimde görev alma (teorik ve klinik) ve araştırma (laboratuar ve klinik onkoloji)

- Yatan ve ayaktan hasta tedavisi

- Onkoloji uzman eğitimine aktif katılım

6.Akdeniz Üniversitesi, Tıp Fakültesi, Antalya-TÜRKİYE (Aralık 1999 – Mayıs 2000)

Derece: Tıbbi Onkolog (Aralık 1999’da olundu)

- Yatan ve ayaktan hasta tedavisi

7.Norfolk & Norwich Hospital, Clinical Oncology Department, Norwich-İNGİLTERE (Ekim 1998– Ekim 1999)

Görev: Klinik Onkoloji Uzmanlığı

- Servis ve kemoterapi ünitesinde eğitim ve çalışma

- Kemoterapi uygulanması

- Serviste vizitlerin organizasyonu

- Haftalık bölümler arası toplantılara katılım

8.Addenbrooke’s Hospital, Clinical Oncology Department, Cambridge-İNGİLTERE (Mart 1999 – Eylül 1999)

Görev: Misafir Onkoloji Uzmanı

- Dr. Helena Earl’ün sarkom, meme ve over kanseri kliniği

9.St. Bartholomew’s Hospital, Medical Oncology Department, Londra-İNGİLTERE (Ekim 1997 Ekim 1998)

Görev: Misafir Araştırma Uzmanı

- Üç çalışmanın tamamlanması ve birinin uluslarası sunumu

- Prof Oliver’in kliniğine katılım ve üriner sistem kanserli hastaların izlemi

- Günlük vizitlere katılım

10.Akdeniz Üniversitesi, Tıp Fakültesi, Antalya-TÜRKİYE (Mart-Ekim 1997 – Ekim-Aralık 1999)

Görev: Onkoloji Uzmanlığı

- Vizitlerden ve poliklinik hastalarının takibinden sorumluluk

- Diğer bölümlerle konsültasyonlar

- Seminerler, haftalık makale saatleri ve diğer toplantılara katılım.

11.Akdeniz Üniversitesi, Tıp Fakültesi, Antalya-TÜRKİYE (Ekim 1996 – Mart 1997)

Derece: İç Hastalıkları Uzmanlığı (Ekim 1996’da olundu)

- Genel kanser hasta takibi

- Dahiliye hasta takibi

12.Akdeniz Üniversitesi, Tıp Fakültesi, Antalya-TÜRKİYE (Kasım 1991 – Ekim 1996)

Görev: İç Hastalıkları Uzmanlığı (En üst %1 dilimde TUS uzmanlık sınavının kazanılması)

- Tıbbi Yoğun Bakım Ünitesinde 16 ay çalışma

- Acil serviste toplam 7 ay çalışma (internlikteki 2 aylık çalışma da dahil)

- 4 kıdemsiz uzman eğitimi

- Tüm İç Hastalıkları alt branşlarından hasta takip ve tedavisi

13.Hacettepe Üniversitesi, Tıp Fakültesi (İngilizce Tıp), Ankara-TÜRKİYE (Eylül 1984 – Haziran 1991)

Derece: Tıp Doktoru (Üniversite sınavında en üst %1 dilimde derece)

- Acil ve acil dışı değişik durumlarda klinik sorumlıluklar

- 7 dalı kapsayan intörnlük eğitimi

Akreditasyon:

• Queensland’de Tıbbi Onkoloji için kayıta kabül, Queensland-AVUSTRALYA, Ekim 2007

• ESMO Tıbbi Onkoloji uluslararası sınavında başarı (150 üstü katılımcıda 7. sıra), Nice-FRANSA, Ekim 2002

• British Council Sponsorluğu ile GMC kayıta kabül, Londra-İNGİTERE, Haziran 1998

• FMGEMS sınavında başarı(Amerika), Ankara-TURKİYE, Ocak1992

Ödüller:

1. “Tıbbi onkoloji araştırma ödülü”, 2. lik, 22. UKK, Antalya-TÜRKİYE, 2017

2. “Bilimsel araştırma ödülü, 1.lik”, 21. UKK, Antalya- TÜRKİYE, 2016

3. “Hemşirelik araştırma ödülü, 2. lik”, 21. UKK, Antalya- TÜRKİYE, 2016

4. “Özel yayın ödülü”, 21. UKK, Antalya- TÜRKİYE, 2016

5. “Bilimsel araştırma ödülü, 2. lik”, 20. UKK, Antalya-, TÜRKİYE, 2015

6. “En iyi bilimsel sunum” ,5. Medikal Onkoloji Kongresi, Antalya- TÜRKİYE, 2014

7. “En iyi poster ödülü”, 4. Ulusal Medikal Onkoloji Kongresi, Antalya- TÜRKİYE, 2007

8. “Sunum ödülü ”, 2. Ulusal Onkoloji Araştırma Toplantısı, Ankara- TÜRKİYE, 2007

9. “Palyatif ve sosyal onkoloji araştırma ödülü, 3. lük” Novartis’den, Antalya- TÜRKİYE, 2006

10. “En iyi onkoloji araştırma ödülü”, 1. Türk Medikal Onkoloji Kongresi, Antalya- TÜRKİYE, 2006

11. “Canada,Terry Fox kanser araştırma ödülü”, Türk Kanser Araştırma Vakfı, Antalya- TÜRKİYE, 2004

12. “Bilimsel araştırma ödülü, 3. lük” Türk Kanser Araştırma Vakfı, Antalya- TÜRKİYE, 2003

13. “En iyi bilimsel sunum ödülü” 15. UKK, Antalya- TÜRKİYE, 2003

Diğer profesyonel aktiviteler ve eğitim:

• Austin Journal of Lung Cancer Research Editoryel Bord üyeliği, Antalya-TÜRKİYE, 2015

• ESMO kursu ders verme teklifi, Ankara- TÜRKİYE, 2006

• Akciğer kanseri oturum başkanlığı, ESMO eğitim toplantısı, Rodos-YUNANİSTAN, 2004

• St.Bartholomew’s Hospital, Stem Cell Transplantation Unit, Londra- İNGİLTERE, 1998

• St.Bartholomew’s Hospital, Statistics Course Programme, Londra- İNGİLTERE, 1998

• St.Bartholomew’s Hospital, Computer Course Programme, Londra- İNGİLTERE, 1998

• The Royal Marsden NHS Trust, Seminar Course in Oncology, Londra-İNGİLTERE, 1998

• Acil Tıp Eğitim Programı, Ankara- TÜRKİYE, 1995

• MSIC Radiology - TYKS Hospital, Turku-FİNLANDİYA, 1990

Ek beceriler:

Çoklu analiz, Tıbbi İstatistik, Python programlama, Yapay zeka uygulaması geliştirme

YAYINLAR

Uluslararası Endeksler:

1. Ersoy F.F., Karayalcin U., Karayalcin B., Sapan M., Bozcuk H., Suleymanlar G., Yakupoglu G. Transfer of Native Insulin through the Peritoneal Membrane during CAPD in Diabetic and Non-Diabetic Patients. Advances in Peritoneal Dialysis. 1995;11: 119-22.

2. Ustun H., Ersoy F.F., Sezer T., Ozcan S., Bozcuk H., Yegin O., Balci M., Suleymanlar G., Yakupoglu G. Effect of Cefodizime on peritoneal mononuclear and polymorphonuclear cell chemotaxis. Advances in Peritoneal Dialysis. 1998;14:154-7.

3. Aslan M., Yucel G., Bozcuk H., Savas B. The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy. Cancer Immunology Immunotherapy, 1998; 47(3):176-81.

4. Bozcuk H., Turner B, Tsetis D.,Thomas JM.,Chan O.,Reznek R.,Ravi R.,Hendry WF.,Oliver RTD. The potential of day 21 CT scan and 3 dimensional construction in predicting need for post chemotherapy surgery in nonseminomatous germ cell tumour. British Journal of Urology, 2000;86:707-13.

5. Bozcuk H, Uslu G, Pestereli E, Samur M, Ozdogan M, Karaveli S, Sargin F, Savas B. Predictors of distant metastasis at presentation in Breast Cancer: A study also evaluating associations among common biological indicators. Breast Cancer Research and Treatment 2001; 68(3): 239-48.

6. Bozcuk H, Martin C. Does treatment delay affect survival in non-small Lung Cancer? A retrospective analysis from a single U.K. centre. Lung Cancer, 2001; 34(2): 243-52.

7. Goonewardane T. I.., Bozcuk H., Oliver R.T.D., Barua J., Philip T., Mair G., Gibbs S. Phase ½ study of synchronous Methotrexate, Cisplatin, Vincristine (MOPq10) chemotherapy and radiation for patients with locally advanced Bladder Cancer. Urologia Internationalis, 2001; 67: 293-7.

8. Samur M, Bozcuk H, Kara A, Ozdogan M, Savas B. Factors associated with utilisation of unproven cancer therapies in Turkey. Supportive Care in Cancer 2001; 9(6): 452-8.

9. Ustun H, Ustun M, Sindel T, Yilmaz S, Bozcuk H, Karpuzoglu G, Savas B. Lipiodol chemoembolization and additional tamoxifen and verapamil as chemosensitizers in unresectable hepatocellular carcinoma with immunohistochemically P-glycoprotein positive cases. Turkish Journal of Cancer, 2001; 31(2): 78-81.

10. Bozcuk H, Erdoğan V, Eken C, Çıplak E, Samur M, Ozdogan M, Savas B. Does awareness of diagnosis make any difference to quality of life? The determinants of emotional functioning in a group of cancer patients in Turkey. Supportive Care in Cancer, 2002; 10(1): 51-7.

11. Samur M, Bozcuk H, Dalmaz G, Karaveli Ş, Köseoğlu FG, Çolak T, Peştereli E. Treatment delay in breast cancer; does it really have an impact on prognosis? Turkish Journal of Cancer, 2002; 32(4): 138-47.

12. Bozcuk H, Kolağası O, Samur M, Yıldız M, Özdoğan M, Artaç M, Savas B. A brief information sheet on opioid effects improves quality of life in cancer patients on opioids. Internet journal of pain, symptom control and palliative care, 2003; 2(2).

13. Samur M, Bozcuk H. A paradigm shift in adjuvant treatment of receptor positive premenapausal breast cancer patients? Not yet! (Letter to the editor). Journal of Clinical Oncology, 2003; 21(12): 2444.

14. Özdoğan M, Samur M, Bozcuk H, Sagtas E, Yıldız M, Artaç M, Savas B. Durable remission of leptomeningeal metastasis of breast cancer with letrozole; a case report and implications of biomarkers on treatment selection. Japanese Journal of Clinical Oncology, 2003; 33: 229-31.

15. Coban E, Samur M, Bozcuk H, Ozdogan M. The value of CEA and CA19-9 in detecting cancer in a group of “High Risk” subjects with gastrointestinal symptoms. International Journal of Biological Markers, 2003; 18 (3): 177-81.

16. Samur M, Bozcuk H, Karaveli Ş, Peştereli E, Özdoğan M, Yıldız M, Artaç M, Savaş B. Reevaluation of baseline staging tests in breast cancer; what should be the standard? Turkish Journal of Cancer, 2003; 33(3):150-3.

17. Samur M, Karaveli S, Bozcuk H, Pestereli E, Ozdogan M, Yildiz M, Artac M, Savas B. A novel method of reporting c-erb-B2 overexpression: correlation with grade but not with other prognostic parameters in breast cancer. Turkish Journal of Medical Sciences, 2003, 33: 363-8.

18. Coban E, Ozdogan M, Tuncer M, Bozcuk H, Ersoy F. The Value of Low-Dose Intraperitoneal Immunoglobulin administration in the treatment of Peritoneal Dialysis Related Peritonitis. Journal of Nephrology, 2004; 17 (3): 427-430.

19. Sanlioglu A, Aydin C, Bozcuk H, Terzioglu E, Luleci G, Sanlioglu S. Fundamental principles of tumor necrosis factor- alpha gene therapy approach and implications for patients with lung carcinoma. Lung Cancer,2004; 44 (2): 199-211.

20. Ozdogan M, Samur M, Bozcuk H, Coban E, Artac M, Kara A, Topcu Z, Sualp Y, Savas B. Do not tell approach: which factors affect relatives’ attitudes against honest disclosure of diagnosis to cancer patients? Supportive Care in Cancer, 2004; 12 (7): 497-502.

21. Bozcuk H, Koyuncu E, Yıldız M, Samur M, Özdoğan M, Artaç M, Çoban E, Savaş B. A simple and accurate prediction model to estimate the intrahospital mortality risk for hospitalised cancer patients. International Journal of Clinical Practice, 2004; 58 (11):1014-1019.

22. Bozcuk H, Bilge U, Koyuncu E, Gulkesen H. An application of Genetic Algorithm in conjunction with other data mining methods for estimating outcome after hospitalization in cancer patients. Medical Science Monitor, 2004; 10(6): CR246-251.

23. Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, Artac M, Altunbas H, Akan I, Savas B. Tumor Necrosis Factor-alpha, Interleukin-6 and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine, 2004; 27 (2-3): 58-65.

24. Ozdogan M, Samur M, Bozcuk H, Aydın H, Coban E, Savas B. Venlafaxine for treatment of chemotherapy induced neuropathic pain. Turkish Journal of Cancer, 2004; 34 (3): 110-113.

25. Ozdogan M, Samur M, Bozcuk H, Coban E, Artac M, Savas B. Is the third line chemotherapy feasible for non small cell lung cancer? A retrospective study. Turkish Journal of Cancer, 2004; 34(1):19-23.

26. Bozcuk H, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Artac M, Ozdogan M, Samur M, Kaya A, Savas B. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer. Medical Science Monitor, 2005; 11 (6): HY11-20.

27. Artac M, Bozcuk H, Ozdogan M, Demiral AN, Sarper A, Samur M, Savas B. Different clinical features of primary and secondary tumours in patients with multiple malignancies. Tumori, 2005;91(4):317-320.

28. Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance / consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)?: A meta-analysis of the published randomized controlled trials. Cancer, 2005; 104(12): 2650-2657.

29. Yildiz M, Ozenci CC, Akan I, Akan S, Sati L, Demir R, Savas B, Ozben T, Samur M, Ozdogan M, Artac M, Bozcuk H. Zoledronic acid induces apoptosis in vitro: its association with Multidrug Resıstance Protein-1 and evidence for synergy with vinblastine. Cell Biology International, 2006; 30(3): 278-282.

30. Bozcuk H, Dalmis B, Samur M, Ozdogan M, Artac M, Savas B. Quality of life in patients with advanced non-small cell lung cancer. Cancer Nursing, 2006; 29(2): 104-110.

31. Bozcuk H, Artac M, Kara A, Ozdogan M, Sualp Y, Topcu Z, Karaagacli A, Yildiz M, Savas B. Does music exposure during chemotherapy improve quality of life in early breast cancer patients? : a pilot study. Medical Science Monitor, 2006; 12(5): CR200-205.

32. Yildiz M, Bozcuk H, Aslan A, Simsek T, Zorlu G, Artac M, Ozdogan M, Savas B, Samur M. Retrospective evaluation of weekly docetaxel in recurrent ovarian cancer: a single centre experience. The internet journal of gynecology and obstetrics, 2006; 6(1).

33. Ozdogan M, Samur M, Artac M, Yildiz M, Savas B, Bozcuk HS. Factors related to truth-telling practice of physicians treating patients with cancer in Turkey. Journal of palliative medicine, 2006; 9(5): 1114-1119.

34. Bulent Y, Zengin N, Aydın F, İlhan M, Isikdogan A, Demir G, Aykan F, Celik I, Dane F, Ustuner Z, Boruban MC, Bozcuk H, Coskun HS, Karaoglu A, Altınbas M, Yamac D, Tek I, Budakoglu B, Utkan G, Ozdemir F, Aksoy F, Ozdemir F, Aksoy S, Ozdemir N, Akbulut H, Buyukcelik A, Icli F. The clinical and pathological features of patients with gastric cancer in Turkey. A Turkish Oncology Group Study. Turkish Journal of Cancer, 2006; 36(3):108-115

35. Ozdogan M, Bozcuk H, Coban E. Low grade inflammation in white coat hypertension. Medical Science Monitor, 2007; 13(12): CR570-573.

36. Ozturk OH, Bozcuk H, Burgucu D, Ekinci D, Ozdogan M, Akca S, Yildiz M. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line. Preliminary results of an in vitro study. Cell Biology International, 2007; 31(9): 1069-1071.

37. Bozcuk H, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Ozdogan M, Demircan A. Recursive partitioning analysis of mediastinal N2 lymph node involvement with selected biomarkers in operable non-small cell lung cancer: A correlative study. Biomarker Insights, 2007; 2: 1-6.

38. Artac M, Bozcuk H. The debate over maintenance is not over in small cell lung cancer (Letter to the editor). Journal of Clinical Oncology, 2007; 25(36): 5840.

39. Korcum AF, Aksu G, Bozcuk H, Pestereli E, Simsek T. Small cell carcinoma of the cervix: a case report. Archives of Gynecology and Obstetrics, 2008; 277(4): 367-370.

40. Aksu MG, Bozcuk HS, Korcum AF. Effect of complementary and alternative medicine during radiotherapy on radiation toxicity. Support Care Cancer, 2008; 16(4): 415-419.

41. Artac M, Bozcuk H, Afacan B, Ozdogan M, Samur M. The impact of waist to hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors. Breast, 2008; 17(4): 418-422.

42. Aksu MG, Bozcuk H, Korcum AF, Sen CA, Tuncel N. The results of postoperative chemoradiotherapy in rectal cancer. Turkish Journal of Cancer, 2008; 38(1): 5-11.

43. Artac M, Pehlivan S, Akcan S, Pehlivan M, Tekinalp G, Itırlı G, Aksoy N, Ozdogan M, Savas B, Bozcuk H. The role of microsatellite instability to predict clinical benefit from irinotecan based regimens in metastatic colorectal cancer. Turkish Journal of Cancer, 2008; 38(2): 49-56.

44. Artac M, Bozcuk H, Pehlivan S, Akcan S, Pehlivan M, Sever T, Ozdogan M, Savas B. The value of XPD and XRCC1 genotype polymorhisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan based regimens. J Cancer Res Clin Oncol, 2010; 136(6): 803-809.

45. Bozcuk H, Artac M, Ozdogan M. Correlates of benefit from neoadjuvant chemotherapy before radiotherapy in non-small cell lung cancer: a meta-analytical approach with meta-regression analysis. J BUON, 2010; 15(1): 43-50.

46. Pehlivan S, Artac M, Sever T, Bozcuk H, Kilincarslan C, Pehlivan M. Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. Cancer Gent Cytogenet, 2010; 201(2): 128-132.

47. Coşkun HS, Kargı A, Ozdogan M, Bozcuk H, Savas B. Leukocytosis, thrombocytosis and hypercalcemia as a triple paraneoplastic syndrome in a patient with squamous cell cafrcinoma of the renal pelvis. Turk J Hematol, 2010; 27: 51-52.

48. Sarper A, Titiz TA, Oz N, Arslan G, Bozcuk H, Demircan A. Results of carinal sleeve lobectomy and sleeve pneumonectomy for lung carcinoma. Turkish J Thorac Cardiovasc Surg, 2010; 18(4): 293-299.

49. Bozcuk H, Ozdogan M, Aykurt O, Topcuoglu F, Ozturk H, Ekinci D, Karadeniz A, Mutlu A, Burgucu D. Urginea Maritima (L.) Baker (Liliaceae) extract induces more cytotoxicity than standard chemotherapeutics in the A549non-small cell lung cancer cell line. Turk J Med Sci, 2011; 41(1): 101-108.

50. Bozcuk H, Ozdogan M. The predictors of the efficacy of high dose chemotherapy and stem cell support in the management of metastatic germ cell cancer. Bratisl Lek Listy 2011; 112(5): 296-304.

51. Artac M, Bozcuk H, Kıyıcı A, Eren OO, Boruban MC, Ozdogan M. Serum leptin level and waist to hip ratio predict the overall survival of metastatic breast cancer patients treated with aromatase inhibitors. Breast Cancer, 2011; Dec 28 (Epub ahead of print).

52. Tatlı AM, Uysal M, Goksu SS, Arslan D, Gunduz S, Ozdogan M, Coskun HS, Bozcuk H, Savas B. Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen. Med Oncol, 2012; 29(3): 1935-1937.

53. Senol Y, Ozdogan M, Bozcuk H. Effects and permenancy of the training program “Communication with cancer patients” on the opinions of the students. J Cancer Educ, 2012; 27(2): 338 -341.

54. Uysal M, Goksu SS, Coskun HS, Savas B, Ozdogan M, Bozcuk H. Intraarticular hemorhage due to Bevacizumab in a patient with metastatic colorectal cancer: a case report. J Med Case Rep, 2012; 6(1): 188. doi: 10.1186/1752-1947-6-188.

55. Bozcuk H, Abali H, Coskun S. Lung Cancer Committee of Turkish Oncology Group. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World J Surgical Oncol, 2012; 10(1): 161. doi: 10.1186/1477-7819-10-161.

56. Kavradim ST, Ozer ZC, Bozcuk H. Hope in people with cancer: a multivariate analysis from Turkey. J Adv Nurs, 2013; 69 (5): 1183-1196.

57. Gunduz S, Elpek GO, Uysal M, Goksu SS, Tatli M, Arslan D, Coskun HS, Bozcuk H, Savas B, Ozdogan M. Coexistance of gastric adenocarcinoma and choriocarcinoma: complete response to trastuzumab and chemotherapy. Case Rep Oncol 2012; 5(2):394-399.

58- Arslan D, Gündüz S, Tural D, Uysal M, Tatlı AM, Başsorgun Cİ, Elpek GÖ, Coşkun HŞ, Bozcuk HŞ, Savaş B. Inflammatory myofibroblastic tumor: a rarely seen submucosal lesion of the stomach. Case Rep Oncol Med. 2013;2013:328108. doi: 10.1155/2013/328108.

59- Zeybek A, Toru S, Ozbudak IH, Sarper A, Oz N, Bozcuk H, Ozbilim G, Demircan A. Clinical and pathologic prognostic factors that are influential in the survival and prognosis of lung adenocarcinomas and invasive predominant subtypes. Int Surg. 2013;98(3):191-199.

60- Kargi A, Uysal M, Bozcuk H, Coskun HS, Savas B, Ozdogan M. The importance of COX-2 expression as prognostic factor in early breast cancer. J BUON. 2013;18(3):579-584.

61- Uysal M, Bozcuk H, Karakilinc H, Goksu S, Tatli AM, Gunduz S, Arslan D, Coskun HS, Savas B. Pesticides and cancer: the first incidence study conducted in Turkey. J Environ Pathol Toxicol Oncol. 2013;32(3):245-249.

62-Yildiz M, Bozcuk H, Tokgun O, Karagur ER, Aykurt O, Akca H. Cyclamen exerts cytotoxicity in solid tumor cell lines: a step towards new cancer agents? Asian Pac J Cancer Prev. 2013; 14(10): 5911-5913.

63- Uysal M, Bozcuk H, Sezgin Göksu S, Murat Tatli A, Arslan D, Gündüz S, Senol Coskun H, Ozdogan M, Savas B. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. Biomed Pharmacother. 2014 May;68(4):409-412.

64- Arican A, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer. 2014; 22(10):2629-2634.

65-Arslan D, Bozcuk H, Gunduz S, Tural D, Tattli AM, Uysal M, Goksu SS, Bassorgun Cİ, Koral L, Coskun HS, Ozdogan M, Savas B. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system. Asian Pac J Cancer Prev. 2014;15(6):2465-2472.

66- Artac M, Turhal NS, Kocer M, Karabulut B, Bozcuk H, Yalcin S, Karaagac M, Gündüz S, Isik N, Uygun K. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. Tumori. 2014;100(2):143-148.

67- Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pac J Cancer Prev. 2014;15(8):3801-3804.

68- Goksu SS, Gunduz S, Unal D, Uysal M, Arslan D, Tatli AM, Bozcuk H, Ozdogan M, Coskun HS. Use of blood transfusion at the end of life: does it have any effects on survival of cancer patients? Asian Pac J Cancer Prev. 2014;15(10):4251-4254.

69- Mutlu H, Gündüz S, Büyükçelik A, Yıldız O, Uysal M, Tural D, Bozcuk H, Coşkun HŞ. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b. Clin Genitourin Cancer. 2014 Dec;12(6):447-450.

70- Arslan D, Uysal M, Tatlı AM, Gunduz S, Goksu SS, Başsorgun Cİ, Coskun HS, Bozcuk H, Savaş B. Her-2 positive gastric cancer presented with thrombocytopenia and skin involvement: a case report. Case Rep Oncol Med. 2014;2014:194636. doi: 10.1155/2014/194636.

71- Tatlı AM, Coşkun HŞ, Uysal M, Arslan D, Sezgin Göksu S, Güenay Gündüz S, Cakal S, Bozcuk HŞ, Savaş B. Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma. Int J Clin Exp Med. 2014;7(8):2191-2196.

72- Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H. Elucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer. Oncol Lett. 2014;8(5):2249-2252. 73- Arslan D, Koca T, Tastekin D, Basaran H, Bozcuk H. Impact of poster presentations on academic knowledge transfer from the oncologist perspective in Turkey. Asian Pac J Cancer Prev. 2014;15(18):7707-7711.

74- Gunduz S, Mutlu H, Goksu SS, Arslan D, Tatli AM, Uysal M, Coskun HS, Bozcuk H, Ozdogan M, Savas B. Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma. Asian Pac J Cancer Prev. 2014;15(20):8843-8846.

75- Goksu SS, Bozcuk H, Uysal M, Ulukal E, Ay S, Karasu G, Soydas T, Coskun HS, Ozdogan M, Savas B. Determinants of opioid efficiency in cancer pain: a comprehensive multivariate analysis from a tertiary cancer centre. Asian Pac J Cancer Prev. 2014;15(21):9301-9305.

76- Bozcuk H, Yıldız M, Artaç M, Kocer M, Kaya Ç, Ulukal E, Ay S, Kılıç MP, Şimşek EH, Kılıçkaya P, Uçar S, Coskun HS, Savas B. A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. Support Care Cancer. 2015;23(6):1759-1767.

77- Sezgin Goksu S, Gunduz S, Unal D, Uysal M, Arslan D, Tatlı AM, Bozcuk H, Ozdogan M, Coskun HS. Use of chemotherapy at the end of life in Turkey. BMC Palliat Care. 2014;13(1):51. doi: 10.1186/1472-684X-13-51. eCollection 2014

78-Yıldırım M, Duman E, Ozturk TT, Kaya V,Parlak C, Varol U,Kaya K, Yıldız M, Bozcuk H. Cancer patients’ level of knowledge about diseases and their expectations from their oncologists. TAF preventive Medicine Bulletin, 2014;13(6): 465-468.

79- Gunduz S, Ozgur O, Bozcuk H, Coşkun HS, Ozdogan M, Erkilic M, Sindel T, Yldlzs A, Ylmaz S, Boz A, Aydin F, Karayalçin B, Savas B. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy. Hepatogastroenterology. 2014;61(134):1529-1534.

80- Uysal M, Ozdogan M, Kargi A, Gunduz S, Sezgin Goksu S, Murat Tatli A, Arslan D, Mutlu H, Senol Coskun H, Bozcuk H. Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer. J BUON. 2014;19(4):980-984.

81- Demirelli S, Erkilic M, Oner AO, Budak ES, Gunduz S, Ozgur O, Bozcuk H, Sindel HT, Boz A. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Nucl Med Commun. 2015;36(4):340-349.

82- Geredeli C, Artac M, Yildirim S, Inal A, Dede I, Guler T, Boruban MC, Koral L, Karaagac M, Zamani AG, Altinok T, Aribas O, Bozcuk H, Demirkazik A. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. Tumour Biol. 2015;36(6):4279-4285.

83- Yildirim M, Kaya V, Demirpence O, Gunduz S, Bozcuk H. Prognostic significance of p53 in gastric cancer: a meta- analysis. Asian Pac J Cancer Prev. 2015;16(1):327-332.

84- Mutlu H, Arslan D, Gündüz S, Tural D, Büyükçelik A, Cihan YB, Aslan T, Bozcuk H, Coşkun HS. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. Chemotherapy. 2014;60(2):107-111

85- Gunduz S, Mutlu H, Tural D, Yıldız Ö, Uysal M, Coskun HS, Bozcuk H. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia Pac J Clin Oncol. 2015. doi: 10.1111/ajco.12358. [Epub ahead of print]

86- Arslan D, Tural D, Koca T, Tastekin D, Kaymak Cerkesli A, Basaran H, Gunduz S, Murat Tatli A, Sezgin Goksu S, Uysal M, Kargi A, Kargi B, Koral L, Ibrahim Bassorgun C, Unal D, Mutlu H, Senol Coskun H, Ozdogan M, Bozcuk H. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer. J BUON. 2015;20(2):573-579.

87- Mutlu H, Musri FY, Yalçın M, Kargi A, Özdogan M, Bozcuk H. Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer. J Cancer Res Ther. 2015;11(2):287-290.

88- Tural D, Kivrak SD, Mutlu H, Erkilic M, Gunduz S, Karakurt M, Musri F, Tuna S, Boz A, Aydin F, Karayalcin B, Bozcuk H, Senol CH. Is there any relation between PET-CT SUVmax value and prognostic factors in locally advanced breast cancer? J BUON. 2015;20(5):1282-1286.

89- Gündüz S, Göksu SS, Arslan D, Tatli AM, Uysal M, Gündüz UR, Sevinç MM, Coşkun HS, Bozcuk H, Mutlu H, Savas B. Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. Mol Clin Oncol. 2015;3(5):1109-1112.

90- Tatli AM, Arslan D, Uysal M, Goksu SS, Gunduz SG, Coskun HS, Ozdogan M, Savas B, Bozcuk HS. Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer. J Cancer Res Ther. 2015;11(4):805-809.

91- Göksu SS, Bozcuk H, Koral L, Çakar B, Gündüz S, Tatlı AM, Arslan D, Uysal M, Koçer M, Artaç M, Karabulut B, Coşkun HS, Özdoğan M, Savaş B. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes? Indian J Cancer. 2015;52(4):517-519.

92- Gunduz S, Bozcuk H, Yıldız M, Goksu SS, Uysal M, Arslan D, Tatlı AM, Mutlu H, Coşkun HS, Ozdogan M. Line of abiraterone acetate in castration-resistant metastatic prostate cancer - Does it matter? report of a multi-institutional experience. Indian J Cancer. 2015;52(4):658-660.

93- Turkoglu MA, Vural V, Erbis H, Coskun HS, Bozcuk H, Ibis M. Liver first approach as an unusual treatment modality for rectal cancer with synchronous liver metastasis:report of a case. Gazi Med J, 2015; 26(3): 117-118.

94- Merdin A, Merdin FA, Gunduz S, Bozcuk H, Coskun HS. Opioid endocrinopathy: a clinical problem in patients with cancer pain. Exp Ther Med. 2016;11(5):1819-1822.

95- Artac M, Coskun HS, Korkmaz L, Kocer M, Turhal NS, Engin H, Dede I, Paydas S, Oksuzoglu B, Bozcuk H, Demirkazık A. Using Interferon alpha before Thyrosine kinase inhibitors may increase survival in patients with metastatic renal carcinoma: a Turkish Oncology Group (TOG) study. Clin Genitourin Cancer, 2016; 14(4):347-353.

96- Artac M, Uysal M, Karaagac M, Korkmaz L, Er Z, Guler T, Boruban MC, Bozcuk H. Prognostic impact of neutrophil/lymphocyte ratio, platelet count, CRP and albumin levels in metastatic colorectal cancer patients treated with FOLFIRI-Bevacizumab. J Gastrointest Cancer, 2017;48(2):176-180.

97- Bozcuk H, Ozcan K, Erdogan C, Mutlu H, Demir M, Coskun S. A comparative study of art therapy in cancer patients receiving chemotherapy and improvement in quality of life by watercolour painting. Complementary Therapies in Medicine, 2017;30: 67-72.

98- Gligorov J, Ataseven B, Verrill M, et al; SafeHer Study Group. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study’s primary analysis of 2573 patients. Eur J Cancer, 2017;82:237-246.

99- Kaya V, Yildirim M, Yazici G, Gunduz S, Bozcuk H, Paydas S. Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis. Asian Pac J Cancer Prev, 2018;19(5):1169-1173.

100- Bozcuk H, Burgucu D, Barut M. A Novel Biologically Active Mixture (Bam) with Anti-Tumoral and Anti-Atherosclerotic Effects: Report of In Vitro Efficacy. J Complement Med Alt Healthcare J, 2018; 5(1):1-4.

101- Ergen SA, Dincbas FO, Yücel B, Altınok P, Akyurek S, Korkmaz Kıraklı E, Ulger S, Etiz D, Yilmaz U, Kılıc D, Bozcuk H. Risk factors of radiation pneumonitis in patients with NSCLC treated with concomitant chemoradiotherapy--Are we underestimating diabetes?--Turkish oncology group (TOG)/Lung cancer study group. Clin Respir J, 2020; doi: 10.1111/crj.13220.

102- Bozcuk H, Yildirim M, Sever O, Mutlu H, Artac M. Checkpoint inhibitors in advanced nonsmall‐cell lung cancer; a Bayesian network meta‐analysis. J Can Res Ther, 2020; 16(4): 828-827.

103- Bozcuk H, Artac M, Mutlu H, Sever O, Yildirim M. Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer. J Oncol Pharm Pract. 2020, Oct 12.

104-Karaagac M, Artac M, Goksu SS, Eryılmaz MK, Coskun HS, Bozcuk H. Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study. EJMO 2020;4(2):172–176.

105- Sarier M, Usta SS, Turgut H, Öztürk SA, Soylu A, Emek M, Kukul E, Bozcuk H, Sepin N. Prognostic value of HPV DNA in Urothelial Carcinoma of the Bladder: A Preliminary Report of 2-Year Follow-up Results. Urol J, 2021, doi: 10.22037/uj.v18i.6429.

106- Miles D, Ciruelos E, Schneeweiss A, et al; PERUSE investigators. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol, 2021; 10:1245-1255.

107- Bozcuk H, Coşkun HŞ, İlhan Y, Göksu SS, Yıldız M, Bayram S, Yerlikaya T, Koçer M, Artaç M, Uğraklı M, Ouisupov A, Aydeniz A, Şahin D, Yalçın G, Saatçi M, Mutlu H, Yıldırım M. Prospective external validation of an updated algorithm to quantify risk of febrile neutropenia in cancer patients after a cycle of chemotherapy. Support Care Cancer, 2022;30(3):2621-2629.

108- Karaçelik T, Kaya B, Korkmaz M, Karaağaç M, Araz M, Eryılmaz MK, Bozcuk HŞ, Artaç M. Prognostic Significance of Adipose Tissue Distribution and Metabolic Activity in PET/CT in Patients with Metastatic Colorectal Cancer. J Gastrointest Cancer, 2022; doi: 10.1007/s12029-022-00819-x. Online ahead of print.

109- Cangır AK, Yumuk PF, Sak SD, Akyürek S, Eralp Y, Yılmaz Ü, Selek U, Eroğlu A, Tatlı AM, Dinçbaş FÖ, Kılıçkap S, Şendur MAN, Dilektaşlı AG, Bozcuk HŞ, Özkök S, Öztop İ, Topkan E, Dilege Ş, Kaya A, Demirkazık A; Turk Oncology Group. Lung Cancer in Turkey. J Thorac Oncol. 2022;17(10):1158-1170.

110-Arslan D, Gündüz S, Akkoyun O, Taşkın P, Lapa TY, Ardahan F, Bozcuk H. Effects of regular exercise, arts(origami), and group psychotherapy on the quality of life, anxiety, depression, patient satisfaction, and hope in cancer patients in remission: a prospective study. Iran Red Crescent Med J. 2022;24(11):E743.

111- Mutlu H, Bozcuk H, Artaç M, Eser İ. First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis. J Cancer Res Ther. 2023; S6-S11. doi: 10.4103/jcrt.jcrt_721_21.

112- Mutlu H, Bozcuk H. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. J Cancer Res Ther. 2023;19(2):394-402. doi: 10.4103/jcrt.JCRT_23_20.

113- Bozcuk HŞ, Şen AE, Artaç M, Kaya B. Unveiling brain region patterns in PET/CT scans for Lung Cancer assessment: A computational AI framework. J Cancer Sci Clin Ther. 2023;7(4):179-185.

Diğer Endeksler:

1. Ustun H., Akca S., Altunbas H., Bozcuk H., Ciftci F., Balci MK. Relationship between the Complications of Type 2 Diabetes Mellitus and Corrected QT in ECG. Turkish Diabetes Annual, 1997; 12:193-5.

2. Akca S., Ustun H., Bozcuk H., Balci M.K., Yardimsever M., Ersoy F. 2 Years’ Experience in Akdeniz University Medical Faculty Intensive Care Unit. Çukurova University Medical Faculty Journal, Vol.23:2, 1998; 82-7.

3. Ustun H., Bozcuk H., Ustun M., Savas B. Comparison of antiemetic efficiency of ondansetron and metoclopramide in patients using non-cisplatin chemotherapy regimens. Turkish Oncology Journal 1999; 13(4): 109-11.

4. Bozcuk H, Coban E, Gelen T, Ozdogan M, Samur M, Savas B. An unusual case of massive hepatomegaly in a patient with peritoneal and pleural mesothelioma at the absence of hepatic involvement. Acta Oncologica Turcica tarafından 2001’de kabul edildi.

5. Ataman F, Korcum AF, Bozcuk H, Şen CA, Samur M, Savas B, Aktan S. Postoperative adjuvant chemotherapy in the management of rectum cancer. The journal for the diseases of colon and rectum, 2003; 13: 51-56.

6. Ataman F, Şimşir V, Şen CA, Bozcuk H, Öğüş M, Erdoğan O, Savaş B. Preliminary results of pancreatic cancer patients with unresectable disease undergoing combined chemoradiotherapy. Şişli Etfal Hastanesi dergisi tarafından 2004’de kabul edildi.

Yazılan Kitap Bölümü:

“Kanser ve Genetik” kitap bölümü A. Nihat Bozcuk ile birlikte yazıldı. “Genetik”, Bölüm 15, 295-304, Palme Kitapçılık, Ekim 2000, Ankara, Türkiye.

Çevirilen Kitap Bölümü:

“Intoxication” bölümü, “Mosby’s Crash Course”, Chapter 39, 387-390, Güneş Kitapçılık, 2001, Ankara, Türkiye (İngilizce’den Türkçe’ye çeviri).

Hobiler:

Tenis, balık avı, suluboya (1. kişisel sergi: Antalya, 2011), gitar ve piyano çalma, savunma sporları, astronomi, kodlama, yapay zeka programlama.